nach oben

Current Rheumatology Reports

Erschienen in:

01.04.2020 | Vasculitis (L Espinoza, Section Editor)

Noninfectious Autoimmune Scleritis: Recognition, Systemic Associations, and Therapy

verfasst von: Alana Nevares, Robert Raut, Bonita Libman, Rula Hajj-Ali

Erschienen in: Current Rheumatology Reports | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The aim of this review is to provide the information necessary for recognizing scleritis in rheumatology patients, recognize associated systemic diseases in scleritis patients referred to rheumatology, and choose the best conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or biologic therapy, based on the most recent data.

Recent Findings

Scleritis is most often associated with systemic conditions, particularly autoimmune conditions. Rheumatologists should be most vigilant about rheumatoid arthritis and ANCA-associated vasculitis. A recent systemic association has been found with IgG4-related disease as well. Most of the therapeutic decisions are based on observational data. Most recently, there is increasing evidence of the role of rituximab for refractory disease.

Summary

Scleritis is a severe inflammatory ocular condition that leads to complications including vision loss. It can precede a systemic autoimmune disease diagnosis, especially in the case of vasculitis. Prompt recognition and adequate therapy are needed in order to avoid serious ocular complications. There is an unmet need for (1) head-to-heat trials on csDMARDs and biologic drugs for the treatment of idiopathic scleritis and (2) randomized controlled trials on the treatment of refractory cases.

Gartner LP, Hiatt JL. Concise histology. Philadelphia: Saunders/Elsevier; 2011.

Yanoff M, Duker JS. Ophthalmology. 5th ed. New York: Elsevier; 2019.

Watson PG, Hayreh SS. Scleritis and episcleritis. Br J Ophthalmol. 1976;60(3):163–91. https://doi.org/10.1136/bjo.60.3.163.CrossRefPubMedPubMedCentral

Honik G, Wong IG, Gritz DC. Incidence and prevalence of episcleritis and scleritis in northern California. Cornea. 2013;32(12):1562–6. https://doi.org/10.1097/ICO.0b013e3182a407c3.CrossRefPubMed

Homayounfar G, Nardone N, Borkar DS, Tham VM, Porco TC, Enanoria WT, et al. Incidence of scleritis and episcleritis: results from the Pacific ocular inflammation study. Am J Ophthalmol. 2013;156(4):752–8. https://doi.org/10.1016/j.ajo.2013.05.026.CrossRefPubMed

Sainz de la Maza M, Molina N, Gonzalez-Gonzalez LA, Doctor PP, Tauber J, Foster CS. Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology. 2012;119(1):43–50. https://doi.org/10.1016/j.ophtha.2011.07.013.CrossRefPubMed

Jabs DA, Mudun A, Dunn JP, Marsh MJ. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol. 2000;130(4):469–76. https://doi.org/10.1016/s0002-9394(00)00710-8.CrossRefPubMed

Clavel G, Gabison E, Semerano L. Corneal and scleral involvement in inflammatory rheumatic disease: rheumatologists and ophthalmologists exchanging views. Joint Bone Spine. 2019. https://doi.org/10.1016/j.jbspin.2019.01.014.

Bowling B, Kanski JJ. Kanski’s clinical ophthalmology: a systematic approach. 8th ed. London: Elsevier; 2016.

10.

Riono WP, Hidayat AA, Rao NA. Scleritis: a clinicopathologic study of 55 cases. Ophthalmology. 1999;106(7):1328–33. https://doi.org/10.1016/s0161-6420(99)00719-8.CrossRefPubMed

11.

Hankins M, Margo CE. Histopathological evaluation of scleritis. J Clin Pathol. 2019;72(5):386–90. https://doi.org/10.1136/jclinpath-2018-205360.CrossRefPubMed

12.

Akpek EK, Thorne JE, Qazi FA, Do DV, Jabs DA. Evaluation of patients with scleritis for systemic disease. Ophthalmology. 2004;111(3):501–6. https://doi.org/10.1016/j.ophtha.2003.06.006.CrossRefPubMed

13.

Iovieno A, Gore DM, Carnt N, Dart JK. Acanthamoeba sclerokeratitis: epidemiology, clinical features, and treatment outcomes. Ophthalmology. 2014;121(12):2340–7. https://doi.org/10.1016/j.ophtha.2014.06.033.CrossRefPubMed

14.

Burton BJ, Cunningham ET Jr, Cree IA, Pavesio CE. Eye involvement mimicking scleritis in a patient with chronic lymphocytic leukaemia. Br J Ophthalmol. 2005;89(6):775–6. https://doi.org/10.1136/bjo.2004.060152.CrossRefPubMedPubMedCentral

15.

Sharma M, Sundar D, Vanathi M, Meel R, Kashyap S, Chawla R, et al. Invasive ocular surface squamous neoplasia masquerading as nodular Scleritis. Ophthalmic Plast Reconstr Surg. 2017;33(2):e45–e7. https://doi.org/10.1097/iop.0000000000000720.CrossRefPubMed

16.

Etminan M, Forooghian F, Maberley D. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study. Cmaj. 2012;184(8):E431–4. https://doi.org/10.1503/cmaj.111752.CrossRefPubMedPubMedCentral

17.

Gaujoux-Viala C, Giampietro C, Gaujoux T, Ea HK, Prati C, Orcel P, et al. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol. 2012;39(2):233–9. https://doi.org/10.3899/jrheum.110865.CrossRefPubMed

18.

Sainz de la Maza M, Foster CS, Jabbur NS. Scleritis associated with systemic vasculitic diseases. Ophthalmology. 1995;102(4):687–92.

19.

Sainz de la Maza M, Foster CS, Jabbur NS. Scleritis associated with rheumatoid arthritis and with other systemic immune-mediated diseases. Ophthalmology. 1994;101(7):1281–6. discussion 7-8.CrossRef

20.

Erhardt CC, Mumford PA, Venables PJ, Maini RN. Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis. 1989;48(1):7–13. https://doi.org/10.1136/ard.48.1.7.CrossRefPubMedPubMedCentral

21.

Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology. 1984;91(10):1253–63.CrossRef

22••.

Caimmi C, Crowson CS, Smith WM, Matteson EL, Makol A. Clinical correlates, outcomes, and predictors of inflammatory ocular disease associated with rheumatoid arthritis in the biologic era. J Rheumatol. 2018;45(5):595–603. https://doi.org/10.3899/jrheum.170437. This single center study reported the clinical characteristics of inflammatory ocular disease in rheumatoid arthritis, extra-skeletal manifestations and mortality in the post-biologic era. CrossRefPubMed

23.

Haynes BF, Fishman ML, Fauci AS, Wolff SM. The ocular manifestations of Wegener’s granulomatosis. Fifteen years experience and review of the literature. Am J Med. 1977;63(1):131–41. https://doi.org/10.1016/0002-9343(77)90125-5.CrossRefPubMed

24.

Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116(6):488–98. https://doi.org/10.7326/0003-4819-116-6-488.CrossRef

25.

Cocho L, Gonzalez-Gonzalez LA, Molina-Prat N, Doctor P, Sainz-de-la-Maza M, Foster CS. Scleritis in patients with granulomatosis with polyangiitis (Wegener). Br J Ophthalmol. 2016;100(8):1062–5. https://doi.org/10.1136/bjophthalmol-2015-307460.CrossRefPubMed

26.

Rothschild PR, Pagnoux C, Seror R, Brezin AP, Delair E, Guillevin L. Ophthalmologic manifestations of systemic necrotizing vasculitides at diagnosis: a retrospective study of 1286 patients and review of the literature. Semin Arthritis Rheum. 2013;42(5):507–14. https://doi.org/10.1016/j.semarthrit.2012.08.003.CrossRefPubMed

27.

Ungprasert P, Crowson CS, Cartin-Ceba R, Garrity JA, Smith WM, Specks U, et al. Clinical characteristics of inflammatory ocular disease in anti-neutrophil cytoplasmic antibody associated vasculitis: a retrospective cohort study. Rheumatology (Oxford). 2017;56(10):1763–70. https://doi.org/10.1093/rheumatology/kex261.CrossRef

28.

Watkins AS, Kempen JH, Choi D, Liesegang TL, Pujari SS, Newcomb C, et al. Ocular disease in patients with ANCA-positive vasculitis. J Ocul Biol Dis Infor. 2009;3(1):12–9. https://doi.org/10.1007/s12177-009-9044-4.CrossRefPubMedPubMedCentral

29.

Sainz-de-la-Maza M, Molina N, Gonzalez-Gonzalez LA, Doctor PP, Tauber J, Foster CS. Scleritis associated with relapsing polychondritis. Br J Ophthalmol. 2016;100(9):1290–4. https://doi.org/10.1136/bjophthalmol-2015-306902.CrossRefPubMed

30.

Bandyopadhyay D, Bandyopadhyay S, Ghosh P, De A, Bhattacharya A, Dhali GK, et al. Extraintestinal manifestations in inflammatory bowel disease: prevalence and predictors in Indian patients. Indian J Gastroenterol. 2015;34(5):387–94. https://doi.org/10.1007/s12664-015-0598-8.CrossRefPubMed

31.

Lanna CC, Ferrari Mde L, Rocha SL, Nascimento E, de Carvalho MA, da Cunha AS. A cross-sectional study of 130 Brazilian patients with Crohn's disease and ulcerative colitis: analysis of articular and ophthalmologic manifestations. Clin Rheumatol. 2008;27(4):503–9. https://doi.org/10.1007/s10067-007-0797-5.CrossRefPubMed

32.

Karmiris K, Avgerinos A, Tavernaraki A, Zeglinas C, Karatzas P, Koukouratos T, et al. Prevalence and characteristics of extra-intestinal manifestations in a large cohort of Greek patients with inflammatory bowel disease. J Crohns Colitis. 2016;10(4):429–36. https://doi.org/10.1093/ecco-jcc/jjv232.CrossRefPubMed

33.

Ungprasert P, Tooley AA, Crowson CS, Matteson EL, Smith WM. Clinical characteristics of ocular sarcoidosis: a population-based study 1976-2013. Ocul Immunol Inflamm. 2019;27(3):389–95. https://doi.org/10.1080/09273948.2017.1386791.CrossRefPubMed

34.

Ohara K, Okubo A, Sasaki H, Kamata K. Intraocular manifestations of systemic sarcoidosis. Jpn J Ophthalmol. 1992;36(4):452–7.PubMed

35.

Saito W, Kotake S, Ohno S. A patient with sarcoidosis diagnosed by a biopsy of scleral nodules. Graefes Arch Clin Exp Ophthalmol. 2005;243(4):374–6. https://doi.org/10.1007/s00417-004-1023-7.CrossRefPubMed

36.

Dursun D, Akova YA, Bilezikci B. Scleritis associated with sarcoidosis. Ocul Immunol Inflamm. 2004;12(2):143–8. https://doi.org/10.1080/09273940490895353.CrossRefPubMed

37.

Hessen M, Eberhart C, Butler N, Akpek EK. Sarcoidosis presenting as scleral nodule. Ocul Immunol Inflamm. 2014;22(4):311–3. https://doi.org/10.3109/09273948.2013.805786.CrossRefPubMed

38.

Paulus YM, Cockerham KP, Cockerham GC, Gratzinger D. IgG4-positive sclerosing orbital inflammation involving the conjunctiva: a case report. Ocul Immunol Inflamm. 2012;20(5):375–7. https://doi.org/10.3109/09273948.2012.709574.CrossRefPubMed

39.

Karim F, de Hoog J, Paridaens D, Verdijk R, Schreurs M, Rothova A, et al. IgG4-related disease as an emerging cause of scleritis. Acta Ophthalmol. 2017;95(8):e795–e6. https://doi.org/10.1111/aos.13376.CrossRefPubMed

40.

Kempen JH, Daniel E, Gangaputra S, Dreger K, Jabs DA, Kacmaz RO, et al. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the systemic immunosuppressive therapy for eye diseases (SITE) cohort study. Ophthalmic Epidemiol. 2008;15(1):47–55. https://doi.org/10.1080/09286580701585892.CrossRefPubMed

41.

Gangaputra S, Newcomb CW, Liesegang TL, Kacmaz RO, Jabs DA, Levy-Clarke GA, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116(11):2188–98.e1. https://doi.org/10.1016/j.ophtha.2009.04.020.CrossRefPubMedPubMedCentral

42.

Pasadhika S, Kempen JH, Newcomb CW, Liesegang TL, Pujari SS, Rosenbaum JT, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148(4):500–9.e2. https://doi.org/10.1016/j.ajo.2009.05.008.CrossRefPubMedPubMedCentral

43.

Daniel E, Thorne JE, Newcomb CW, Pujari SS, Kacmaz RO, Levy-Clarke GA, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149(3):423–32.e1–2. https://doi.org/10.1016/j.ajo.2009.09.026.CrossRefPubMed

44.

Suhler EB, Lim LL, Beardsley RM, Giles TR, Pasadhika S, Lee ST, et al. Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging, randomized, clinical trial. Ophthalmology. 2014;121(10):1885–91. https://doi.org/10.1016/j.ophtha.2014.04.044. This small randomized trial showed efficacy of ritxuimab on the treatment of refractory scleritis. CrossRefPubMed

45.

Cao JH, Oray M, Cocho L, Foster CS. Rituximab in the treatment of refractory noninfectious scleritis. Am J Ophthalmol. 2016;164:22–8. https://doi.org/10.1016/j.ajo.2015.12.032.CrossRefPubMed

46.

Doctor P, Sultan A, Syed S, Christen W, Bhat P, Foster CS. Infliximab for the treatment of refractory scleritis. Br J Ophthalmol. 2010;94(5):579–83. https://doi.org/10.1136/bjo.2008.150961.CrossRefPubMed

47.

Durrani K, Kempen JH, Ying GS, Kacmaz RO, Artornsombudh P, Rosenbaum JT, et al. Adalimumab for ocular inflammation. Ocul Immunol Inflamm. 2017;25(3):405–12. https://doi.org/10.3109/09273948.2015.1134581.CrossRefPubMed

48.

Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785–96.e3. https://doi.org/10.1016/j.ophtha.2013.09.048.CrossRefPubMed

49.

Silpa-Archa S, Oray M, Preble JM, Foster CS. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Acta Ophthalmol. 2016;94(6):e400–6. https://doi.org/10.1111/aos.13015.CrossRefPubMed

50.

Knickelbein JE, Tucker WR, Bhatt N, Armbrust K, Valent D, Obiyor D, et al. Gevokizumab in the treatment of autoimmune non-necrotizing anterior Scleritis: results of a phase I/II clinical trial. Am J Ophthalmol. 2016;172:104–10. https://doi.org/10.1016/j.ajo.2016.09.017.CrossRefPubMedPubMedCentral

51.

Bottin C, Fel A, Butel N, Domont F, Remond AL, Savey L, et al. Anakinra in the treatment of patients with refractory Scleritis: a pilot study. Ocul Immunol Inflamm. 2018;26(6):915–20. https://doi.org/10.1080/09273948.2017.1299869.CrossRefPubMed

52.

Pujari SS, Kempen JH, Newcomb CW, Gangaputra S, Daniel E, Suhler EB, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology. 2010;117(2):356–65. https://doi.org/10.1016/j.ophtha.2009.06.060.CrossRefPubMed

53.

Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–32. https://doi.org/10.1056/NEJMoa0909905.CrossRefPubMedPubMedCentral

54.

Albini TA, Zamir E, Read RW, Smith RE, See RF, Rao NA. Evaluation of subconjunctival triamcinolone for nonnecrotizing anterior scleritis. Ophthalmology. 2005;112(10):1814–20. https://doi.org/10.1016/j.ophtha.2005.05.008.CrossRefPubMed

55.

Tu EY, Culbertson WW, Pflugfelder SC, Huang A, Chodosh JC. Therapy of nonnecrotizing anterior scleritis with subconjunctival corticosteroid injection. Ophthalmology. 1995;102(5):718–24. https://doi.org/10.1016/s0161-6420(95)30963-3.CrossRefPubMed

56.

Watson PW, Hazleman BL. The sclera and systemic disorders. Philadelphia: Saunders; 1976.

Titel: Noninfectious Autoimmune Scleritis: Recognition, Systemic Associations, and Therapy
verfasst von: Alana Nevares
Robert Raut
Bonita Libman
Rula Hajj-Ali
Publikationsdatum: 01.04.2020
Verlag: Springer US
Erschienen in: Current Rheumatology Reports / Ausgabe 4/2020
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-020-0885-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen